Mirae Asset Global ETFs Holdings’s Cartesian Therapeutics RNAC Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32.3K	Buy	5,253 +133	+3%	+$947	﹤0.01%	2984
2025 Q4	$36.9K	Buy	5,120 +244	+5%	+$1.97K	﹤0.01%	2992
2025 Q3	$49.8K	Sell	4,876 -180	-4%	-$2.02K	﹤0.01%	2945
2025 Q2	$52.5K	Sell	5,056 -964	-16%	-$10.3K	﹤0.01%	2872
2025 Q1	$79.3K	Buy	6,020 +234	+4%	+$4.18K	﹤0.01%	2727
2024 Q4	$104K	Buy	5,786 +1,789	+45%	+$36.2K	﹤0.01%	2679
2024 Q3	$64.4K	Buy	3,997 +2,370	+146%	+$37K	﹤0.01%	2863
2024 Q2	$43.9K	Buy	+1,627	New	+$38.8K	﹤0.01%	2819

Other funds holding RNAC

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's RNAC Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings increased its Cartesian Therapeutics (RNAC) stake by 2.6% in Q1 2026, buying an estimated $947 and bringing the position to 5,253 shares worth $32.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2984.

Mirae Asset Global ETFs Holdings first reported a position in RNAC in Q2 2024 and has held it in 8 quarters since. The position peaked at $104K in Q4 2024. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

Mirae Asset Global ETFs Holdings held 5,253 shares of Cartesian Therapeutics worth $32.3K as of Q1 2026.
Mirae Asset Global ETFs Holdings bought 133 Cartesian Therapeutics shares in Q1 2026, an estimated $947.
Cartesian Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q1 2026, its #2984 holding.
Mirae Asset Global ETFs Holdings first reported a position in Cartesian Therapeutics in Q2 2024 and has held it in 8 quarters since.
Mirae Asset Global ETFs Holdings's Cartesian Therapeutics position peaked at $104K in Q4 2024.
83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.